Bỉ - Tiếng Pháp - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

hikma farmacêutica s.a. - cytarabine 1 g/10 ml - solution injectable - 100 mg/ml - cytarabine 2000 mg - cytarabine

Bỉ - Tiếng Pháp - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - cytarabine 1 g/10 ml - solution à diluer pour perfusion - 100 mg/ml - cytarabine 2000 mg - cytarabine

Bỉ - Tiếng Pháp - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - virus varicelle-zona, vivant, atténué >= 2000 ufp - poudre et solvant pour solution injectable - virus varicelle - varicella, live attenuated

Thụy Sĩ - Tiếng Pháp - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tozinameranum - konzentrat zur herstellung einer injektionsdispersion - tozinameranum 30 µg pro dosi, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas) pro dosi, 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum pro dosi, 1,2-distearoyl-sn-glycero-3-phosphocholinum pro dosi, cholesterolum pro dosi, saccharum pro dosi, natrii chloridum pro dosi, natrii hydroxidum, dinatrii phosphas dihydricus pro dosi, kalii dihydrogenophosphas pro dosi, kalii chloridum pro dosi, acidum hydrochloridum, aqua ad iniectabile, natrium 0.16 mg et kalium 0.01 mg pro dosi. - comirnaty ist indiziert für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus hervorgerufenen covid-19-erkrankung bei personen ab 12 jahren - les vaccins

Bỉ - Tiếng Pháp - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - virus varicelle-zona, vivant, atténué >= 2000 ufp - poudre et solvant pour solution injectable - virus varicelle - varicella, live attenuated

Thụy Sĩ - Tiếng Pháp - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tozinameranum - gebrauchsfertige injektionsdispersion für personen ab 12 jahren - suspension: tozinameranum 0.1 mg/ml, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, pro praeparatione. - les vaccins

Thụy Sĩ - Tiếng Pháp - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tozinameranum - konzentrat zur herstellung einer injektionsdispersion - suspension: tozinameranum 0.1 mg/ml, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, 1 ml corresp.. - les vaccins

Thụy Sĩ - Tiếng Pháp - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tozinameranum, riltozinameranum - comirnaty® original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion für personen ab 18 jahren - suspension: tozinameranum 15 µg pro dosi, riltozinameranum 15 µg pro dosi, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, pro dosi. - comirnaty original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion ist indiziert für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus hervorgerufenen covid-19-erkrankung bei personen ab 18 jahren - les vaccins

Liên Minh Châu Âu - Tiếng Pháp - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals pour felidae, - chats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. des immunités ont été démontrées une semaine après la primovaccination pour les composants rhinotrachéite, calicivirus, chlamydophila felis et panleucopénie. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Liên Minh Châu Âu - Tiếng Pháp - EMA (European Medicines Agency)

ceva santé animale - vaccin inactivé de coxiella burnetii, souche nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.